Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Lung Neoplasms 3Adenocarcinoma of Lung 2Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 42Carboplatin 24Cyclophosphamide 20Paclitaxel 19Nivolumab 17Cisplatin 15fludarabine 14Gemcitabine 12aldesleukin 10Docetaxel 10Bevacizumab 9Magnetic Resonance Spectroscopy 8Trastuzumab 7Specimen Handling 7Drug Therapy 7Pemetrexed 6Oxaliplatin 6Ipilimumab 6Interleukin-2 6Fluorouracil 6Cetuximab 6Blood Specimen Collection 6sargramostim 5pegfilgrastim 5avelumab 5Topotecan 5Taxes 5Irinotecan 5palbociclib 4durvalumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Hydroxychloroquine × Thoracic × Clear all
NCT05733000 2023-03-10

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Northwestern University

Phase 2 Recruiting
94 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma of Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡